In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors

Michael D'Angelica, Howard Karpoff, Marc Halterman, Jennifer Ellis, David Klimstra, Diane Edelstein, Michael Brownlee, Howard Federoff, Yuman Fong

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In vivo cytokine gene transfer may greatly simplify autologous tumor vaccine production. Herpes simplex viral amplicon vectors (HSV) are efficient gene-transfer vehicles and may overcome many limitations of prior gene- transfer methods. The interleukin-2 (IL-2) and β-galactosidase genes (lac) were inserted into an HSV amplicon vector and tested in a subcutaneous squamous cell carcinoma of lung origin to determine the efficiency of in vivo gene transfer and the utility of such a direct gene-transfer approach in cancer therapy. Gene transfer and expression were assessed by histochemical staining and enzyme-linked immunosorbent assay (ELISA). Growth of injected tumors as well as non-injected tumors remote from the site of injection was assessed. Assessment of lymphocytic infiltrates into tumors was performed by immunohistochemistry. Survival was recorded. Direct in vivo injection of established tumors with a HSVil2 resulted in efficient gene transfer and production of IL-2 in the injected tumor but not at tumors remote from the sites of injection. There was a significant suppression of growth of the tumors injected with HSVil2 (P < 0.01) when compared with tumors injected with HSV without il2. Of note, growth of tumors remote from sites of HSVi12 injection was also retarded and treatment was associated with a significant (P < 0.05) improvement in survival. Direct intratumoral administration of HSV amplicon vectors can result in efficient transfer of cytokine genes and have antitumor efficacy. HSV vectors are therefore potentially useful agents in such in vivo gene-therapy strategies and simplify cytokine antitumor gene- therapy strategies.

Original languageEnglish (US)
Pages (from-to)265-271
Number of pages7
JournalCancer Immunology Immunotherapy
Volume47
Issue number5
DOIs
StatePublished - 1999

Fingerprint

Herpes Simplex
Genetic Therapy
Interleukin-2
Neoplasms
Genes
Injections
Cytokines
Growth
Galactosidases
Cancer Vaccines
Lac Operon
Squamous Cell Carcinoma
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Staining and Labeling
Gene Expression
Lung

Keywords

  • Cytokines
  • Immunotherapy
  • Squamous tumors

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

D'Angelica, M., Karpoff, H., Halterman, M., Ellis, J., Klimstra, D., Edelstein, D., ... Fong, Y. (1999). In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. Cancer Immunology Immunotherapy, 47(5), 265-271. https://doi.org/10.1007/s002620050530

In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. / D'Angelica, Michael; Karpoff, Howard; Halterman, Marc; Ellis, Jennifer; Klimstra, David; Edelstein, Diane; Brownlee, Michael; Federoff, Howard; Fong, Yuman.

In: Cancer Immunology Immunotherapy, Vol. 47, No. 5, 1999, p. 265-271.

Research output: Contribution to journalArticle

D'Angelica, M, Karpoff, H, Halterman, M, Ellis, J, Klimstra, D, Edelstein, D, Brownlee, M, Federoff, H & Fong, Y 1999, 'In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors', Cancer Immunology Immunotherapy, vol. 47, no. 5, pp. 265-271. https://doi.org/10.1007/s002620050530
D'Angelica, Michael ; Karpoff, Howard ; Halterman, Marc ; Ellis, Jennifer ; Klimstra, David ; Edelstein, Diane ; Brownlee, Michael ; Federoff, Howard ; Fong, Yuman. / In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. In: Cancer Immunology Immunotherapy. 1999 ; Vol. 47, No. 5. pp. 265-271.
@article{ffad06cfd9b5498a934759a41f66f12e,
title = "In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors",
abstract = "In vivo cytokine gene transfer may greatly simplify autologous tumor vaccine production. Herpes simplex viral amplicon vectors (HSV) are efficient gene-transfer vehicles and may overcome many limitations of prior gene- transfer methods. The interleukin-2 (IL-2) and β-galactosidase genes (lac) were inserted into an HSV amplicon vector and tested in a subcutaneous squamous cell carcinoma of lung origin to determine the efficiency of in vivo gene transfer and the utility of such a direct gene-transfer approach in cancer therapy. Gene transfer and expression were assessed by histochemical staining and enzyme-linked immunosorbent assay (ELISA). Growth of injected tumors as well as non-injected tumors remote from the site of injection was assessed. Assessment of lymphocytic infiltrates into tumors was performed by immunohistochemistry. Survival was recorded. Direct in vivo injection of established tumors with a HSVil2 resulted in efficient gene transfer and production of IL-2 in the injected tumor but not at tumors remote from the sites of injection. There was a significant suppression of growth of the tumors injected with HSVil2 (P < 0.01) when compared with tumors injected with HSV without il2. Of note, growth of tumors remote from sites of HSVi12 injection was also retarded and treatment was associated with a significant (P < 0.05) improvement in survival. Direct intratumoral administration of HSV amplicon vectors can result in efficient transfer of cytokine genes and have antitumor efficacy. HSV vectors are therefore potentially useful agents in such in vivo gene-therapy strategies and simplify cytokine antitumor gene- therapy strategies.",
keywords = "Cytokines, Immunotherapy, Squamous tumors",
author = "Michael D'Angelica and Howard Karpoff and Marc Halterman and Jennifer Ellis and David Klimstra and Diane Edelstein and Michael Brownlee and Howard Federoff and Yuman Fong",
year = "1999",
doi = "10.1007/s002620050530",
language = "English (US)",
volume = "47",
pages = "265--271",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "5",

}

TY - JOUR

T1 - In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors

AU - D'Angelica, Michael

AU - Karpoff, Howard

AU - Halterman, Marc

AU - Ellis, Jennifer

AU - Klimstra, David

AU - Edelstein, Diane

AU - Brownlee, Michael

AU - Federoff, Howard

AU - Fong, Yuman

PY - 1999

Y1 - 1999

N2 - In vivo cytokine gene transfer may greatly simplify autologous tumor vaccine production. Herpes simplex viral amplicon vectors (HSV) are efficient gene-transfer vehicles and may overcome many limitations of prior gene- transfer methods. The interleukin-2 (IL-2) and β-galactosidase genes (lac) were inserted into an HSV amplicon vector and tested in a subcutaneous squamous cell carcinoma of lung origin to determine the efficiency of in vivo gene transfer and the utility of such a direct gene-transfer approach in cancer therapy. Gene transfer and expression were assessed by histochemical staining and enzyme-linked immunosorbent assay (ELISA). Growth of injected tumors as well as non-injected tumors remote from the site of injection was assessed. Assessment of lymphocytic infiltrates into tumors was performed by immunohistochemistry. Survival was recorded. Direct in vivo injection of established tumors with a HSVil2 resulted in efficient gene transfer and production of IL-2 in the injected tumor but not at tumors remote from the sites of injection. There was a significant suppression of growth of the tumors injected with HSVil2 (P < 0.01) when compared with tumors injected with HSV without il2. Of note, growth of tumors remote from sites of HSVi12 injection was also retarded and treatment was associated with a significant (P < 0.05) improvement in survival. Direct intratumoral administration of HSV amplicon vectors can result in efficient transfer of cytokine genes and have antitumor efficacy. HSV vectors are therefore potentially useful agents in such in vivo gene-therapy strategies and simplify cytokine antitumor gene- therapy strategies.

AB - In vivo cytokine gene transfer may greatly simplify autologous tumor vaccine production. Herpes simplex viral amplicon vectors (HSV) are efficient gene-transfer vehicles and may overcome many limitations of prior gene- transfer methods. The interleukin-2 (IL-2) and β-galactosidase genes (lac) were inserted into an HSV amplicon vector and tested in a subcutaneous squamous cell carcinoma of lung origin to determine the efficiency of in vivo gene transfer and the utility of such a direct gene-transfer approach in cancer therapy. Gene transfer and expression were assessed by histochemical staining and enzyme-linked immunosorbent assay (ELISA). Growth of injected tumors as well as non-injected tumors remote from the site of injection was assessed. Assessment of lymphocytic infiltrates into tumors was performed by immunohistochemistry. Survival was recorded. Direct in vivo injection of established tumors with a HSVil2 resulted in efficient gene transfer and production of IL-2 in the injected tumor but not at tumors remote from the sites of injection. There was a significant suppression of growth of the tumors injected with HSVil2 (P < 0.01) when compared with tumors injected with HSV without il2. Of note, growth of tumors remote from sites of HSVi12 injection was also retarded and treatment was associated with a significant (P < 0.05) improvement in survival. Direct intratumoral administration of HSV amplicon vectors can result in efficient transfer of cytokine genes and have antitumor efficacy. HSV vectors are therefore potentially useful agents in such in vivo gene-therapy strategies and simplify cytokine antitumor gene- therapy strategies.

KW - Cytokines

KW - Immunotherapy

KW - Squamous tumors

UR - http://www.scopus.com/inward/record.url?scp=0032916801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032916801&partnerID=8YFLogxK

U2 - 10.1007/s002620050530

DO - 10.1007/s002620050530

M3 - Article

VL - 47

SP - 265

EP - 271

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 5

ER -